Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
Jazz Pharmaceuticals (JAZZ) shares fell 6.9% since its last earnings report. Q2 2026 adjusted EPS missed estimates at $5.71, but revenues rose 16% YoY to $1.21B, beating expectations. The company raised 2026 revenue guidance to $4.60-$4.75B. Xywav sales grew 13% YoY, while Xyrem sales declined 14% YoY. Oncology sales increased 32% YoY, driven by Zepzelca's 42% growth.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on sales performance across product lines and updates full-year guidance, influencing trader expectations.
Market read
Earnings and guidance update are primary drivers for short-term trading decisions on JAZZ.
What to watch
Higher SG&A and R&D expense guidance may constrain profitability.
Background
Jazz Pharmaceuticals' Q2 2026 earnings were released, showing mixed results with revenue beating estimates and EPS missing consensus.
Ticker impact
Jazz Pharmaceuticals reported Q2 2026 earnings with EPS miss, revenue beat and raised full-year revenue guidance.
Modest upside if guidance is fully priced in; downside risk if market focuses on EPS miss.
Revenue beat and guidance raise are material, while EPS miss is modest; traders may adjust positions based on guidance.
Market effects
Positive for biotech/pharma sector as revenue guidance lift may boost peers.
US biotech market may see modest uplift.
Limited to pharma investors.
Counterpoint
EPS miss could signal deeper margin pressure despite revenue growth.
Key entities
- CompanyJazz Pharmaceuticals
US-listed biopharma reporting Q2 earnings and raising revenue guidance.
